Fig. 2

IL-33 is required for ILC2 egress from BM. A Plasma IL-33 in WT mice at time points up to 24 h after CLP (n = 3–5 mice/group). B Representative flow cytometry plots and C bar graphs showing percentages of BM ILC2p and lung ILC2 in WT mice after PBS or recombinant murine sST2 injection (10 μg sST2 in 200 μl PBS) 30 min prior to CLP. After 24 h, lung and BM were collected for flow analysis (n = 5 mice/group). D Representative flow cytometry plots and bar graph of BM ILC2p (E) and lung ILC2 (F) percentages and absolute number of WT, Il33^−/−, St2^−/− mice at 24 h after CLP (n = 3–5 mice/group). G Flow cytometry of BM ILC2p from mice treated with PBS or rmIL-33 (40 µg/kg B.W, i.v) for 24 h (n = 5 mice/group). H BM ILC2p percentage and absolute number in PBS or rmIL-33-treated mice (n = 5 mice/group). I BM ILC2p number in control mice were normalized as 100%. The percentage of remaining BM ILC2p cells after IL-33 treatment in control mice was analyzed. J Bone marrow cells were treated with/without IL-2 (10 ng/ml), IL-7 (10 ng/ml) and IL-33 (50 ng/ml), and frequencies of ILC2p were analyzed by flow cytometry. K The frequencies of ILC2p in bone marrow at 24 h after stimulation of IL-2, IL-7 or IL-33 (n = 3 per group). L The absolute number of ILC2p in bone marrow at 24 h after stimulation of IL-2, IL-7 or IL-33 (n = 3 per group). Data are shown as mean ± SEM. *P < 0.05, **P < 0.01